RX
Ran Xu
Physician · Newton-Wellesley Hospital
Credentials: · · ·
History
- 2025–Present
Research
Duvelisib plus romidepsin in relapsed/refractory T cell lymphomas: a phase 1b/2a trial
Nature Medicine · 2024 · 50 citations
Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1
Blood · 2022 · 37 citations
Targetable leukaemia dependency on noncanonical PI3Kγ signalling
Nature · 2024 · 35 citations
- DW
4 papers
3 papers
3 papers · 1 as a resident
- AL
2 papers
- CT
2 papers
- ES
2 papers
- JH
2 papers
2 papers
